Sapropterin continues to hold a leading position in the phenylketonuria (PKU) treatment market, particularly among patients with BH4-responsive PKU ...Maternal PKU Management ... Strong PKU Volume Momentum.
“These data mark an important milestone in our efforts to advance the understanding and treatment of PKU,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka.